Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)-Reference-Cited by-同舟云学术

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)

Published:2024-04-13 Issue:3 Volume:19 Page:423-433
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Nishioka Naoya,Imai Hisao^ORCID,Endo Masahiro,Notsu Akifumi,Doshita Kosei,Igawa Satoshi,Yokouchi Hiroshi,Ninomiya Takashi,Tokito Takaaki,Soda Sayo,Fujiwara Takasato,Asao Tetsuhiko,Nakamichi Shinji,Kawamura Takahisa,Inomata Minehiko,Nakashima Kazuhisa,Ito Kentaro,Goto Yasuhiro,Umeda Yukihiro,Hirai Soichi,Ushio Ryota,Yokoo Keiki,Takeda Takayuki,Fukui Tomoya,Ishihara Masashi,Osaki Takashi,Kubo Sousuke,Fujiwara Takumi,Yamamoto Chie,Tsuda Takeshi,Tamura Nobumasa,Hosokawa Shinobu,Chihara Yusuke,Ikeda Satoshi,Furuya Naoki,Nakahara Yoshiro,Miura Satoru,Okamoto Hiroaki

Funder

Saitama Medical University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01048-x.pdf

Reference25 articles.

1. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958–67.

2. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.

3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

4. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.

5. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–34.